From “going out” to “being taken to the door”: the international appeal of Peger Biotech's (02565) innovation assets is taking shape

The Zhitong Finance App learned that for an innovative drug company, the value of international cooperation has never been just “how many collaborations have been signed”. The more important questions are: why did the collaboration happen, who is looking for whom, and why are partners willing to invest their core technology platforms, R&D resources, and time into a certain group of candidates.

Judging from the recent progress of cooperation, Peger Biotech (02565)'s international cooperation is undergoing a notable change: as the company's innovation pipeline in the field of obesity and metabolic diseases continues to advance and the differentiated characteristics of more candidate assets gradually emerge, more and more international innovative technology platforms are beginning to actively approach Peger, hoping to apply their own technology to innovators independently developed by Peger, and cooperate around new product forms and development paths.

Instead of seeking cooperation for the purpose of internationalization, international cooperation begins to actively gather around these assets when the assets themselves are attractive enough.

1. Continuous international cooperation is not three isolated incidents

From Rani Therapeutics, to Lexaria Bioscience, to SN BioScience, Peger has recently continuously established R&D partnerships with international innovation platforms with different technology paths. If you just break down these events one by one, they correspond to different technical directions such as oral delivery, absorption and pharmacokinetic optimization, and long-term delivery; but if you put them on the same timeline, the background actually points to the same more important logic: overseas platforms are continuing to select Peger's innovators to verify whether these molecules can form new product forms under different cutting-edge technology paths.

Rani represents an innovative oral biomacromolecule delivery route. The core problem is how to break through the limitations of traditional methods of administration of peptides and biomacromolecules; Lexaria further explores the possibility of innovative oral delivery and pharmacokinetic optimization; while SN BioScience applied its long-acting drug delivery platform to various Peger's innovative peptide drug candidates, including APGP6, to explore longer duration of action, better dosage solutions, and more differentiated product forms. The three collaborations are not repeated; instead, they broaden the product boundaries of the same batch of independent innovation assets from different dimensions.

Therefore, what is really worth paying attention to is that “Peggy has one more partner”, but rather that this kind of cooperation is showing continuity: platform-based companies from different countries and different technology routes are willing to use their core technology to test in combination with Peger's molecules. When this choice ceases to be a one-off incident and begins to occur continuously, it itself constitutes a verification of the candidate's external appeal.

2. Platforms need good molecules, and high-quality molecules also need more product forms

Ultimately, the commercial value of drug delivery and formulation platforms must be reflected through specific pharmaceutical products. A platform can have excellent technology, but without sufficient competitive bottom elements, it is difficult for even the best delivery technology to actually transform into marketable products. Therefore, it is not an irrelevant technical move for platform-based companies to select which candidates to cooperate; it is essentially a judgment on the potential development potential, differentiation space, and commercial imagination of candidate assets.

For Peger, the meaning of these collaborations is not “using someone else's technology to make up for his own shortcomings.” On the contrary, the core of the collaboration has always been Peger's own innovators. What the external platform is doing is to further open up new product possibilities based on these molecules: a high-quality candidate doesn't have to have only one dosage form, one dosage frequency, or one product positioning in the future; it can be developed into oral versions, longer-lasting versions, versions with different pharmacokinetic characteristics through different delivery and formulation techniques, and even form differentiated product portfolios for different patients' needs.

Molecules determine the upper limit of assets, and delivery technology determines the boundaries of product forms.

This also means that Peger is gradually extending from the traditional development idea of “one molecule corresponds to one product” to the development logic of “using high-quality molecules as the core and expanding multiple product forms through multi-technology platforms”. For an innovative pharmaceutical company focusing on obesity and metabolic diseases, this model can not only increase the potential development value of single molecules, but also significantly increase options for future foreign cooperation.

3. From technical verification to BD, international cooperation is forming a clearer gradient

Early material transfers, technical verification, or joint research are not equivalent to officially authorized transactions, nor should they be simply packaged as having achieved commercial value. But they have an important meaning: they provide a low-cost and efficient pre-verification mechanism for deeper cooperation. Only when molecules and platforms actually produce attractive data can subsequent joint development, product licensing, and even commercial cooperation have a more solid foundation.

Taking this collaboration with SN BioScience as an example, the collaboration does not only revolve around a single candidate molecule, but rather covers various innovative peptide assets, including APGP6, at once, and clearly ensures a space for further discussions on licensing, co-development, and commercialization cooperation while the research results are positive. This structure itself shows that technical verification is not the end point, but rather a pre-screening process for the two parties to determine whether it is worth entering the next stage of cooperation.

Seen from this perspective, the continuous emergence of Rani, Lexaria, and SN Bioscience is establishing a clearer path for Peger's international cooperation: first, an international technology platform actively searches for and selects potential candidates, then confirms the combined value through technical verification, and then decides whether to enter deeper product cooperation and BD based on the results. As more preclinical and clinical data are gradually generated, this path may become an important source of future global cooperation for the company.

4. What has really been verified is not only delivery technology, but Pegger Asset itself

If you only look at a single collaboration, the market can easily understand it as an ordinary R&D event; but when different technology platforms continue to cooperate around candidates from the same company, what investors really need to observe is whether a kind of “asset appeal” is being formed behind these collaborations. For Peger, the answer is gradually becoming clear: the company's candidates are not only being promoted within the internal R&D system, but are also beginning to become targets that external innovative technology platforms are willing to actively engage, invest resources, and jointly verify.

This is why recent international cooperation is much more important than just adding a few overseas partners. What is more noteworthy is that in the past, Pegger is gradually moving from needing to actively demonstrate its R&D capabilities to the outside world, making the asset itself an entry point for cooperation. Technology platforms can come from the US, South Korea, or other markets, and technology routes can vary, but the core around the collaboration has not changed—it is still an innovator developed independently by Peger.

As more and more international technology platforms want to apply their technology to Peger's molecules, it is not only a certain delivery technology, but also the appeal of Pegger's independent innovation assets themselves.

For innovative drug companies, this change is more important than “an increase in the number of international collaborations.” Because assets with real global value will ultimately not only rely on the company itself to tell the story; as data, differentiating characteristics, and development potential continue to be seen, external resources will begin to actively gather around high-quality assets. What Peggy is currently experiencing is this kind of change from “taking the initiative to go out” to “taking the initiative to come to the door with more and more cooperation.”